Actively Recruiting
Evaluating Caplyta Versus Placebo for Treating Social Anxiety Disorder in Adults
Led by Jason Careri · Updated on 2026-09-15
40
Participants Needed
1
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether Caplyta lumateperone can reduce the frequency and severity of social anxiety symptoms in adults diagnosed with Social Anxiety Disorder SAD. The study compares Caplyta to a placebo to understand its effects on this condition. The trial is a randomized, double-blind, phase 4 study designed to assess treatment outcomes in adults aged 18 to 65 years. Participants will take either Caplyta 42 mg daily or a matching placebo for 8 weeks. They will visit the clinic once every week for checkups and tests throughout the treatment period. The study uses a parallel design and includes a placebo comparator group to evaluate the effects of Caplyta on SAD symptoms. During the study, participants will undergo regular assessments including psychiatric evaluations and rating scales such as the Liebowitz Social Anxiety Scale LSAS, Hamilton Depression Rating Scale HAM-D, and Clinical Global Impression of Severity CGI-S. Researchers will measure changes in social anxiety symptoms from baseline to the study endpoint at week 8. Safety monitoring and adherence to treatment will be maintained throughout the trial.
CONDITIONS
Brief Title
Caplyta Versus Placebo for Adults With Social Anxiety Disorder
Research Team
A
Ann Draine
B
Brittany Smith
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here